

# Association of Schizophrenia With the Risk of Breast Cancer Incidence

## A Meta-analysis

Chuanjun Zhuo, MD, PhD; Patrick Todd Triplett, MD

[+ Supplemental content](#)

**IMPORTANCE** Patients with schizophrenia are considered to have many risk factors for the development of cancer. However, the incidence of breast cancer in women with schizophrenia compared with the general population remains uncertain.

**OBJECTIVE** To perform an updated meta-analysis to evaluate the association between schizophrenia and the risk of breast cancer.

**DATA SOURCES** A systematic search of the PubMed and EMBASE databases was conducted using the search terms *schizophrenia*, *schizophrenic*, *psychosis*, combined with *breast and cancer*, *tumor*, *neoplasm*, or *carcinoma*. The final literature search was performed on August 15, 2017.

**STUDY SELECTION** Cohort studies reporting the standardized incidence ratio (SIR) for the risk of breast cancer in women with schizophrenia compared with the general population.

**DATA EXTRACTION AND SYNTHESIS** The meta-analysis adhered to Meta-analysis of Observational Studies in Epidemiology and the *Cochrane Handbook for Systematic Reviews of Interventions*. Data extraction was performed independently. A random-effects model was used to pool the results, and a recently proposed prediction interval was calculated to describe the heterogeneity.

**MAIN OUTCOMES AND MEASURES** The SIR for the risk of breast cancer in women with schizophrenia compared with the general population or those without schizophrenia.

**RESULTS** Twelve cohorts including 125 760 women were included in this meta-analysis. The results of the meta-analysis showed that schizophrenia was associated with a significantly increased risk of breast cancer incidence in women (SIR, 1.31; 95% CI, 1.14-1.50;  $P < .001$ ), with significant heterogeneity ( $P < .001$ ;  $I^2 = 89\%$ ). Substantial between-study variance was also suggested by the wide prediction interval (0.81-2.10), which indicated that it is possible that a future study will show a decreased breast cancer risk in women with schizophrenia compared with the general population. The subgroup analysis results showed that the association was not significantly affected by whether breast cancer cases were excluded at baseline or the sample size of the included studies.

**CONCLUSIONS AND RELEVANCE** The incidence of breast cancer in women with schizophrenia is higher than that of the general female population. However, significant heterogeneity exists among the included studies. Women with schizophrenia deserve intensive prevention and treatment of breast cancer.

JAMA Psychiatry. doi:10.1001/jamapsychiatry.2017.4748  
Published online March 7, 2018.

**Author Affiliations:** Department of Psychiatric Laboratory, Tianjin Medical University, Tianjin, China (Zhuo); Department of Psychiatric Neuroimaging Faculty, Tianjin Mental Health Center, Tianjin, China (Zhuo); Department of Psychiatry and Behavioral Sciences, The Johns Hopkins School of Medicine, Baltimore, Maryland (Triplett).

**Corresponding Author:** Chuanjun Zhuo, MD, PhD, Department of Psychiatric Laboratory, Tianjin Medical University, No. 22 Qixiangtai Rd, Heping District, Tianjin, 300070 China ([chuanjunzhuotjmh@163.com](mailto:chuanjunzhuotjmh@163.com)).

The status of physical health in patients with schizophrenia has become an important topic in health care management research.<sup>1</sup> Because patients with schizophrenia may be prone to have an unhealthy lifestyle, they are vulnerable to many chronic diseases, such as metabolic disorders,<sup>2,3</sup> diabetes,<sup>4,5</sup> and cardiovascular diseases.<sup>6,7</sup> However, the risk of cancer in patients with schizophrenia remains uncertain.<sup>8</sup> Although the health of patients with schizophrenia is complicated by many risk factors for the development of cancer, including smoking,<sup>9,10</sup> alcohol and substance abuse,<sup>11</sup> obesity,<sup>12,13</sup> and lack of exercise,<sup>14,15</sup> epidemiologic studies have shown inconsistent results. In a previous meta-analysis of cohort studies,<sup>16</sup> the overall risk of cancer was not statistically significantly increased in patients with schizophrenia compared with the general population without schizophrenia. The results of subsequent analyses have shown that the association between schizophrenia and cancer risk may not be explained only by the risk factors related to an unhealthy lifestyle; many other factors, including genetic mechanisms, may be involved in the interactions between schizophrenia and cancer pathogenesis.<sup>17</sup> Because schizophrenia has been associated with lowered risks of many types of cancer, including colorectal cancer, malignant melanoma, and prostate cancer,<sup>16</sup> it has been hypothesized that the genetic factors involved in the pathogenesis of schizophrenia may be protective against cancer.<sup>18-20</sup> However, the association between schizophrenia and breast cancer remains uncertain. The results of subgroup analyses from a previous meta-analysis have shown an association between schizophrenia and an increased risk of breast cancer compared with the general female population.<sup>16</sup> A subsequent systematic review challenged these results by including more recent studies, but the results were mixed.<sup>21</sup> Many published cohort studies were not included in the previous meta-analysis,<sup>22-26</sup> and the results of some previously included cohort studies have been updated.<sup>27-29</sup> Another meta-analysis<sup>30</sup> used a conventional method that evaluates the heterogeneity among studies with the  $I^2$  statistic and combines the results with the random-effects model. However, this method was challenged by recent findings that  $I^2$  may not be an appropriate index of heterogeneity, and instead, a prediction interval (PI) that describes the heterogeneity in a random-effects meta-analysis should be reported to quantify the heterogeneity.<sup>31</sup> Therefore, we thought it important to perform an updated meta-analysis regarding the association between schizophrenia and the risk of breast cancer with the reporting of the PI. The results of this study may lead to better prevention and early treatment of breast cancer in women with schizophrenia.

## Methods

This systematic review and meta-analysis was designed and performed in accordance with the Meta-analysis of Observational Studies in Epidemiology<sup>32</sup> and the *Cochrane Handbook for Systematic Reviews of Interventions* guidelines.<sup>33</sup> The study was approved by Tianjin Medical University.

## Key Points

**Question** Are women with schizophrenia at a higher risk for breast cancer?

**Findings** In this meta-analysis of 12 cohort studies that included 125 760 women and in which conventional methods of meta-analysis had been used, schizophrenia in women was associated with an increased breast cancer incidence compared with the general population. However, substantial between-study variance is present that is reflected by the wide prediction interval.

**Meaning** The results suggest that the incidence of breast cancer in women with schizophrenia is higher than that of the general female population; however, significant heterogeneity exists among the included studies, and it is possible that a future study will show a decreased breast cancer risk in women with schizophrenia compared with the general population.

## Literature Search

We systematically searched the PubMed and EMBASE databases with the terms *schizophrenia*, *schizophrenic*, and *psychosis*, combined with *breast* and *cancer*, *tumor*, *neoplasm*, or *carcinoma*. The search was limited to studies in humans that were published in English. We also manually screened the reference lists of original and review articles. The final literature search was performed on August 15, 2017.

## Inclusion and Exclusion Criteria

Studies that fulfilled the following criteria were included: (1) published as full-length articles in English, (2) designed as cohort studies (prospective or retrospective, regardless of the sample size and follow-up duration), (3) included adult women (age  $\geq 18$  years), (4) schizophrenia identified as exposure at baseline, (5) the general population without a diagnosis of schizophrenia was used as a control, (6) documented incidence of breast cancer on follow-up, and (7) reported the adjusted standardized incidence ratios (SIRs), at least adjusted for age, and their corresponding 95% CIs for breast cancer incidence in women with schizophrenia compared with controls. The diagnosis of schizophrenia and the confirmation of breast cancer cases were consistent with the criteria applied in the original articles. If studies with overlapping participants were encountered, the reports with the larger sample size were included in the present meta-analysis. Abstracts, letters to the editor, reviews, and investigations with designs other than a cohort study were excluded from the present analysis. Studies reporting breast cancer-related mortality rather than incidence were also excluded because the mortality outcome may be affected by many factors other than breast cancer incidence, such as comorbidities and treatments.

## Data Extraction and Quality Evaluation

We performed the literature search, data extraction, and quality assessment independently, according to the predefined inclusion criteria. Discrepancies were resolved by consensus. The following data regarding the characteristics of the studies were extracted: name of first author, year of publication, country where the study was conducted, sample size, source of the

study population, years of follow-up, number of breast cancer cases, strategies for confirmation of breast cancer cases, and whether cancer incidence before the diagnosis of schizophrenia was excluded. The Newcastle-Ottawa Scale<sup>34</sup> was used to evaluate the quality of the included studies. This scale ranges from 1 (lowest quality) to 9 (highest quality) stars and judges each study regarding the aspects of study group selection, comparability of the groups, and ascertainment of the outcome of interest.

### Statistical Analysis

Data of SIRs and the lower and upper limits of their 95% CIs were extracted to calculate log SIRs and their corresponding SEs. The logarithmically transformed SIRs and their corresponding SEs were used to stabilize the variance and normalize the distribution. The Cochran *Q* test and the *I*<sup>2</sup> statistic were used to evaluate the heterogeneity among the included cohort studies.<sup>30</sup> A random-effects model was used for the meta-analysis of the SIR data because this model is considered to produce a more generalized result by considering heterogeneity between studies.<sup>33</sup> A PI was calculated based on the methods provided by Borenstein et al<sup>31</sup> indicating the range of a true SIR of a future study in 95% of all populations. Sensitivity analyses by omitting 1 study at a time were performed to evaluate the robustness of the results.<sup>35</sup> Because a previous systematic review has indicated that studies with more than 100 breast cancer cases tend to show an evident association between schizophrenia and the risk of breast cancer,<sup>21</sup> we performed stratified analyses according to whether the number of breast cancer cases in the included studies was over 100. Subgroup analysis was performed according to whether the cases of breast cancer that occurred before the diagnosis of schizophrenia were excluded in each study. Potential publication bias was assessed by funnel plots with the Egger regression asymmetry test.<sup>36</sup> RevMan, version 5.1 (Cochrane Collaboration) and Stata software, version 12.0 (StataCorp) were used for the statistical analyses.

## Results


### Literature Search Results

The literature searching process and study identification are summarized in **Figure 1**. In brief, 832 records were identified after initial database searching and exclusion of the duplicate records. Further screening of titles and abstracts excluded 801 records, mainly because they were irrelevant to the aim of the study. For the 31 records that underwent full-text review, 20 were excluded because 2 of them included patients with mental diseases other than schizophrenia, 7 were reports of already included cohorts, 3 did not report the incidence of breast cancer, 6 only reported data regarding breast cancer mortality, and the other 2 did not provide outcome data as SIRs.

### Study Characteristics and Quality Evaluation

Overall, 11 database-derived retrospective cohort studies<sup>8,22-26,37-41</sup> were included. Because 1 study<sup>36</sup> included data from 2 different cohorts, 12 cohorts were included in our meta-analysis. The

**Figure 1. Flowchart of the Literature Search**



SIR indicates standardized incidence ratio.

baseline characteristics of the included cohorts are reported in the eTable in the **Supplement**. There was a total of 125 760 women included in the studies. Overall, the studies were published between 1992 and 2016 and included participants from Europe,<sup>23,25,38-40</sup> the United States,<sup>22,37</sup> and Asia.<sup>8,24,26,37,41</sup> Five cohorts included hospitalized patients with schizophrenia,<sup>23,26,38-40</sup> while the others did not specify the source of the patients. The number of women with schizophrenia included in each study varied from 1388 to 46 447, and the number of the breast cancer cases ranged from 42 to 1042. Six studies<sup>8,23-26,39</sup> excluded the breast cancer cases that occurred before the diagnosis of schizophrenia; the other studies did not specify. The qualities of the included studies were generally good, with Newcastle-Ottawa Scale values between 6 and 8.


### Schizophrenia and the Incidence of Breast Cancer

The meta-analysis results of the 12 cohorts showed that schizophrenia was associated with a significantly increased risk of breast cancer incidence in women (SIR, 1.31; 95% CI, 1.14-1.50; *P* < .001) (**Figure 2**), with significant heterogeneity (*P* < .001; *I*<sup>2</sup> = 89%). The existence of substantial between-study variance is reflected by the wide PI (0.81-2.10). Accordingly, it is possible that a future study will show a decreased breast cancer risk in women with schizophrenia compared with the general population. The findings of sensitivity by omitting 1 study at a time did not significantly change the results, with the SIR varying between 1.29 and 1.38 (all *P* < .01).

### Results of Subgroup Analyses


The results of subgroup analyses showed that the association between schizophrenia and an increased breast cancer incidence was significant in studies in which breast cancer occurred before the diagnosis of schizophrenia were excluded

Figure 2. Incidence of Breast Cancer in Women With Schizophrenia



Pooled results of 12 cohorts indicated that schizophrenia was associated with a significantly increased risk of breast cancer incidence in women. IV indicates inverse-variance; SIR, standardized incidence ratio.

Figure 3. Subgroup Analyses According to Whether the Breast Cancer Cases That Occurred Before the Diagnosis of Schizophrenia Were Excluded



Subgroup analysis results showed that the association between schizophrenia and increased risk of breast cancer incidence in women was not significantly affected by whether breast cancer cases were excluded at baseline. IV indicates inverse-variance; SIR, standardized incidence ratio.

(SIR, 1.34; 95% CI, 1.20-1.51;  $P < .001$ ;  $I^2 = 84\%$ ) (Figure 3) and in studies with more than 100 breast cancer cases (SIR, 1.31; 95% CI, 1.18-1.46;  $P < .001$ ;  $I^2 = 84\%$ ) (Figure 4), but the association between schizophrenia and breast cancer incidence was not significant in studies that did not specify the exclusion of breast cancer cases that occurred before the diagnosis of schizophrenia (SIR, 1.38; 95% CI, 0.89-2.14;  $P = .15$ ;  $I^2 = 91\%$ ) (Figure 3) or in studies with fewer than 100 breast cancer cases (SIR, 1.50; 95% CI, 0.78-2.87;  $P = .23$ ;  $I^2 = 93\%$ ) (Figure 4). However, the differences between subgroups were not statistically significant ( $P = .90$  and  $P = .70$  for subgroup interaction).


Publication Bias

The funnel plot for the association between schizophrenia and breast cancer incidence was symmetric on visual inspection (eFigure 1 in the Supplement). The Egger regression test also did not indicate a potential publication bias ( $P = .64$ ).

Discussion

In this study, by pooling the results of all available cohort studies with the conventional method of meta-analysis, we found

Figure 4. Subgroup Analyses According to the Number of Breast Cancer Cases in Each Study



Subgroup analysis results showed that the association between schizophrenia and increased risk of breast cancer incidence in women was not significantly affected by the sample size of the included studies. IV indicates inverse-variance; SIR, standardized incidence ratio.

that women with schizophrenia are at a higher risk for the incidence of breast cancer compared with the general population. These results were not significantly affected by whether only breast cancer cases after the diagnosis of schizophrenia were considered or the sample size of the studies. However, substantial between-study variance is present, which is reflected by the wide PI (0.81-2.10). Accordingly, it is possible that a future study will show a decreased breast cancer risk in women with schizophrenia compared with the general population. Because breast cancer is the most common cancer in women, affecting 1 in 9 women during their lifetime,<sup>42</sup> our findings highlight that intensive prevention and treatment against breast cancer are warranted for women with schizophrenia.

The results of this study have important clinical implications. First, we found that schizophrenia in women was associated with an increased breast cancer incidence compared with the general population, which is contrary to the previous hypothesis that schizophrenia may be protective against cancer. These results, together with our recent meta-analysis results showing no association with lung cancer risk but a reduced hepatic cancer risk in schizophrenia (data available on request), indicated that the association between schizophrenia and cancer risk may be complicated and depend on the cancer site. Second, because the current status of breast cancer prevention and treatment options are less optimal in women with schizophrenia,<sup>43</sup> our results highlight that women with schizophrenia deserve focused care for breast cancer screening and treatment. These gaps were also reflected by the results of a recent study showing that patients with schizophrenia are at a significantly increased risk of cancer mortality compared with the general population or individuals without schizophrenia,<sup>44</sup> although the incidence of cancer in these

patients may not necessarily differ from that of the general population. For the early prevention of breast cancer, an initial evaluation is needed to stratify the risk of breast cancer in women with schizophrenia. Subsequently, antipsychotics that may increase the prolactin level and produce a higher breast cancer risk should be avoided in high-risk women. Regular screening, including imaging or biomarker tests, should be performed. If an early diagnosis of breast cancer is made in women with schizophrenia, collaborations with oncologists are needed for clinical psychiatrists to make an optimal treatment recommendation. In addition, every effort should be made to improve the patients' adherence during the prevention, treatment, and follow-up.

An important strength of our study is that we calculated the PI to describe the heterogeneity in a random-effects meta-analysis. We found substantial between-study variance, which is reflected by the wide PI (0.81-2.10). Accordingly, it is possible that a future study will show a decreased breast cancer risk in women with schizophrenia compared with the general population. Within the context of significant heterogeneity among the previously published cohort studies focusing on the association between schizophrenia and breast cancer risk, whether performing an epidemiologic study is sufficient to answer the question is of concern. Instead, large database research, such as deep neural network analysis centered on a genetic or other biological association between schizophrenia and breast cancer risk, may be optimal. These studies are warranted.

As for the potential mechanisms underlying the association between an increased breast cancer risk in women with schizophrenia, many factors may be involved (eFigure 2 in the Supplement). First, many clinical conditions that are com-

monly seen in patients with schizophrenia may also be risk factors for the development of breast cancer, such as obesity, nulliparity, and breastfeeding.<sup>45</sup> As breast cancer may be a hormone-dependent cancer, a significant positive association between plasma prolactin levels and the risk of breast cancer, has been observed<sup>46</sup>; in addition, increased prolactin levels have been documented in women with schizophrenia, particularly for those receiving certain antipsychotics.<sup>47</sup> Finally, schizophrenia and breast cancer may share some other pathophysiologic factors during their development, including pathways involved in angiogenesis<sup>48</sup> and cell cycle regulation.<sup>49</sup> However, further experimental studies are needed to determine the exact mechanisms underlying the association between schizophrenia and breast cancer incidence.

### Limitations

Our study has some limitations that should be considered when interpreting the results. First, as inherent in other meta-analyses of observational studies, we could not exclude the possibility that some residual factors may confound the association between schizophrenia and breast cancer, such as dietary factors and the use of antipsychotics. As a common shortcoming of meta-analyses of observational studies, the results of this study could not indicate a causative association between schizophrenia and breast cancer in women. In addition, significant heterogeneity remained in our meta-analysis, and the source of the heterogeneity could not be fully analyzed because we did not have access to individual pa-

tient data of the included cohorts. Also, we did not include studies found in other databases, not written in English, or published as a conference abstract. We acknowledge this as a limitation. However, including literature reports from PubMed, EMBASE, and the Cochrane Library published only in English should have covered the majority of the cases. Including conference abstracts that did not undergo peer review may potentially cause other bias. Finally, factors such as age at onset of breast cancer, treatment, or cancer subtypes may substantially affect the association between schizophrenia and breast cancer incidence. These factors were generally not reported in the original studies; therefore, they could not be analyzed accordingly in the meta-analysis. Future studies are needed to determine the association between schizophrenia and the different pathologic subtypes of breast cancer as well as whether the association may be affected by the woman's age at breast cancer onset, antipsychotic medications used, and the cancer subtype.

### Conclusions

The results of this meta-analysis demonstrated that women with schizophrenia are at a higher risk for the incidence of breast cancer, compared with the general female population, although substantial between-study variance is present. Intensive screening and treatment for breast cancer in women with schizophrenia are clinically important.

#### ARTICLE INFORMATION

**Accepted for Publication:** December 27, 2017.

**Published Online:** March 7, 2018.

doi:10.1001/jamapsychiatry.2017.4748

**Author Contributions:** Dr Zhuo had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Both authors.

**Acquisition, analysis, or interpretation of data:** Zhuo

**Drafting of the manuscript:** Both authors.

**Critical revision of the manuscript for important intellectual content:** Both authors.

**Administrative, technical, or material support:** Zhuo.

**Study supervision:** Zhuo.

**Conflict of Interest Disclosures:** None reported.

**Funding/Support:** This work was supported by grants 2014KR02 from the Tianjin Health Bureau Foundation and 17JCZDJC35700 from the Key Projects of the Natural Science Foundation of Tianjin, China (Dr Zhuo).

**Role of the Funder/Sponsor:** The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Additional Contribution:** Hongqing Zhuang, MD, PhD (Department of Radiation Oncology, Peking University Third Hospital), helped the literature searching, data extraction, and quality assessment. There was no financial compensation.

#### REFERENCES

- Oud MJ, Meyboom-de Jong B. Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. *BMC Fam Pract*. 2009;10:32.
- Zhai D, Lang Y, Feng Y, et al. Early onset of cardiometabolic risk factor profiles in drug naive adolescents and young adults with first-episode schizophrenia. *Schizophr Res*. 2017;190:60-62.
- Zhai D, Cui T, Xu Y, et al. Cardiometabolic risk in first-episode schizophrenia (FES) patients with the earliest stages of both illness and antipsychotic treatment. *Schizophr Res*. 2017;179:41-49.
- Morris A. Diabetes: linking diabetes and schizophrenia. *Nat Rev Endocrinol*. 2017;13(3):126.
- Vancampfort D, Correll CU, Galling B, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. *World Psychiatry*. 2016;15(2):166-174.
- Li M, Fan YL, Tang ZY, Cheng XS. Schizophrenia and risk of stroke: a meta-analysis of cohort studies. *Int J Cardiol*. 2014;173(3):588-590.
- Fan Z, Wu Y, Shen J, Ji T, Zhan R. Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. *J Psychiatr Res*. 2013;47(11):1549-1556.
- Grinshpoon A, Barchana M, Ponizovsky A, et al. Cancer in schizophrenia: is the risk higher or lower? *Schizophr Res*. 2005;73(2-3):333-341.
- Miyauchi M, Kishida I, Suda A, et al. Long term effects of smoking cessation in hospitalized schizophrenia patients. *BMC Psychiatry*. 2017;17(1):87.
- Cather C, Pachas GN, Cieslak KM, Evins AE. Achieving smoking cessation in individuals with schizophrenia: special considerations. *CNS Drugs*. 2017;31(6):471-481.
- Chang CK. Impact of additive alcohol and substance use disorders on the mortality of people with schizophrenia and mood disorders. *Evid Based Ment Health*. 2016;19(2):55.
- Li Q, Du X, Zhang Y, et al. The prevalence, risk factors and clinical correlates of obesity in Chinese patients with schizophrenia. *Psychiatry Res*. 2017;251:131-136.
- Sugai T, Suzuki Y, Yamazaki M, et al. High prevalence of obesity, hypertension, hyperlipidemia, and diabetes mellitus in Japanese outpatients with schizophrenia: a nationwide survey. *PLoS One*. 2016;11(11):e0166429.
- Stubbs B, Chen LJ, Chung MS, Ku PW. Physical activity ameliorates the association between sedentary behavior and cardiometabolic risk among inpatients with schizophrenia: a comparison versus controls using accelerometry. *Compr Psychiatry*. 2017;74:144-150.
- Vancampfort D, Stubbs B, Probst M, et al. Physical activity as a vital sign in patients with schizophrenia: evidence and clinical recommendations. *Schizophr Res*. 2016;170(2-3):336-340.

16. Catts VS, Catts SV, O'Toole BI, Frost AD. Cancer incidence in patients with schizophrenia and their first-degree relatives—a meta-analysis. *Acta Psychiatr Scand*. 2008;117(5):323-336.
17. Fond G, Macgregor A, Attal J, et al. Antipsychotic drugs: pro-cancer or anti-cancer? a systematic review. *Med Hypotheses*. 2012;79(1):38-42.
18. Bushe CJ, Hodgson R. Schizophrenia and cancer: in 2010 do we understand the connection? *Can J Psychiatry*. 2010;55(12):761-767.
19. Hodgson R, Wildgust HJ, Bushe CJ. Cancer and schizophrenia: is there a paradox? *J Psychopharmacol*. 2010;24(4)(suppl):51-60.
20. Jablensky A, Lawrence D. Schizophrenia and cancer: is there a need to invoke a protective gene? *Arch Gen Psychiatry*. 2001;58(6):579-580.
21. Bushe CJ, Bradley AJ, Wildgust HJ, Hodgson RE. Schizophrenia and breast cancer incidence: a systematic review of clinical studies. *Schizophr Res*. 2009;114(1-3):6-16.
22. McGinty EE, Zhang Y, Guallar E, et al. Cancer incidence in a sample of Maryland residents with serious mental illness. *Psychiatr Serv*. 2012;63(7):714-717.
23. Ji J, Sundquist K, Ning Y, Kendler KS, Sundquist J, Chen X. Incidence of cancer in patients with schizophrenia and their first-degree relatives: a population-based study in Sweden. *Schizophr Bull*. 2013;39(3):527-536.
24. Lin CY, Lane HY, Chen TT, Wu YH, Wu CY, Wu VY. Inverse association between cancer risks and age in schizophrenic patients: a 12-year nationwide cohort study. *Cancer Sci*. 2013;104(3):383-390.
25. Osborn DP, Limburg H, Walters K, et al. Relative incidence of common cancers in people with severe mental illness: cohort study in the United Kingdom THIN primary care database. *Schizophr Res*. 2013;143(1):44-49.
26. Chen LY, Hung YN, Chen YY, et al. Cancer incidence in young and middle-aged people with schizophrenia: nationwide cohort study in Taiwan, 2000-2010 [published online November 21, 2016]. *Epidemiol Psychiatr Sci*.
27. Mortensen PB. The incidence of cancer in schizophrenic patients. *J Epidemiol Community Health*. 1989;43(1):43-47.
28. Mortensen PB. The occurrence of cancer in first admitted schizophrenic patients. *Schizophr Res*. 1994;12(3):185-194.
29. Barak Y, Achiron A, Mandel M, Mirecki I, Aizenberg D. Reduced cancer incidence among patients with schizophrenia. *Cancer*. 2005;104(12):2817-2821.
30. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002;21(11):1539-1558.
31. Borenstein M, Higgins JP, Hedges LV, Rothstein HR. Basics of meta-analysis:  $I^2$  is not an absolute measure of heterogeneity. *Res Synth Methods*. 2017;8(1):5-18.
32. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting: Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. *JAMA*. 2000;283(15):2008-2012.
33. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions: Version 5.1.0. The Cochrane Collaboration. <http://training.cochrane.org/handbook>. Updated June 2017. Accessed January 18, 2018.
34. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2010. [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp). Updated 2014. Accessed October 15, 2017.
35. Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. *Int J Epidemiol*. 2008;37(5):1148-1157.
36. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315(7109):629-634.
37. Gulbinat W, Dupont A, Jablensky A, et al. Cancer incidence of schizophrenic patients: results of record linkage studies in three countries. *Br J Psychiatry Suppl*. 1992;18(18):75-83.
38. Lichtermann D, Ekelund J, Pukkala E, Tanskanen A, Lönnqvist J. Incidence of cancer among persons with schizophrenia and their relatives. *Arch Gen Psychiatry*. 2001;58(6):573-578.
39. Dalton SO, Mellemejkær L, Thomassen L, Mortensen PB, Johansen C. Risk for cancer in a cohort of patients hospitalized for schizophrenia in Denmark, 1969-1993. *Schizophr Res*. 2005;75(2-3):315-324.
40. Goldacre MJ, Kurina LM, Wotton CJ, Yeates D, Seagroatt V. Schizophrenia and cancer: an epidemiological study. *Br J Psychiatry*. 2005;187:334-338.
41. Barak Y, Levy T, Achiron A, Aizenberg D. Breast cancer in women suffering from serious mental illness. *Schizophr Res*. 2008;102(1-3):249-253.
42. Warner E. Clinical practice: breast-cancer screening. *N Engl J Med*. 2011;365(11):1025-1032.
43. Aggarwal A, Pandurangi A, Smith W. Disparities in breast and cervical cancer screening in women with mental illness: a systematic literature review. *Am J Prev Med*. 2013;44(4):392-398.
44. Zhuo C, Tao R, Jiang R, Lin X, Shao M. Cancer mortality in patients with schizophrenia: systematic review and meta-analysis. *Br J Psychiatry*. 2017;211(1):7-13.
45. Li H, Sun X, Miller E, et al. BMI, reproductive factors, and breast cancer molecular subtypes: a case-control study and meta-analysis. *J Epidemiol*. 2017;27(4):143-151.
46. Wang M, Wu X, Chai F, Zhang Y, Jiang J. Plasma prolactin and breast cancer risk: a meta-analysis. *Sci Rep*. 2016;6:25998.
47. De Hert M, Peuskens J, Sabbe T, et al. Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. *Acta Psychiatr Scand*. 2016;133(1):5-22.
48. Lopes R, Soares R, Figueiredo-Braga M, Coelho R. Schizophrenia and cancer: is angiogenesis a missed link? *Life Sci*. 2014;97(2):91-95.
49. Wang Y, He G, He L, McGrath J. Do shared mechanisms underlying cell cycle regulation and synaptic plasticity underlie the reduced incidence of cancer in schizophrenia? *Schizophr Res*. 2011;130(1-3):282-284.